BACKGROUND Zilver PTX, a paclitaxel-eluting stent for FP lesions, provides superior outcomes to angioplasty and
For its drawing, sensitivity, p{X $ c j D ¼ 1}, and specificity, p{X < c j D ¼ 0}, were calculated as 
RESULTS
Baseline characteristics of the study population are shown in Table 1 
ONE-YEAR INCIDENCE OF CLINICAL OUTCOMES.
Of a total of 690 enrolled patients, 64 patients (9%) died and 44 (6%) dropped out by the end of the study.
Of the remaining 697 lesions (84%) in 592 patients (86%), 150 lesions experienced MALE, whereas 547
were free from MALE. Of the 547 MALE-free lesions, 481 lesions had their patency assessed at 12 AE 2 months, whereas 66 did not. Patency was assessed by the core laboratory-reviewed angiography in 208 of the 481 lesions (43%). Figure 1 shows the estimated clinical outcomes at 1 year. One-year incidence of restenosis in the overall population was estimated to be 37% (95% CI: 33 to 41), whereas 1-year MALE was observed in 22% (95% CI: 19 to 25), indicating that MALE accounted for 58% in lesions with restenosis. Table 2 shows the logistic regression analysis used to investigate the predictors for 1-year restenosis. When angiographic data were used for analysis, reference vessel diameter (<4.5 cm) and lesion length ($8 cm) were independent predictors for restenosis, whereas lesion length ($16 cm), distal EEM area (#27 mm 2 ), and MSA (#12 mm 2 ) were independent predictors in analysis with angiographic and IVUS data. The use of IVUS data provided a larger area under the ROC curve for predicting restenosis (0.70 vs. 0.65, p ¼ 0.040). In stratification analysis, 1-year restenosis rate was as low as 15% in cases with none of these risk factors, whereas it reached 50% in those with $2 risk factors ( Figure 2 ).
PREDICTORS FOR RESTENOSIS.
We supplementarily analyzed the association of these risk factors with MALE, using the generalized linear mixed model with a logit link function. In the univariate analysis, small reference vessel diameter (<4.5 mm), small distal EEM area (#27 mm 2 ), and small MSA (#12 mm 2 ), but not the other baseline characteristics, were significantly associated with MALE (all p < 0.05). In the multivariate model in which these 3 variables with significance were entered as fixed effects, only small distal EEM area (#27 mm 2 ) had a significant and independent association with MALE; its adjusted odds ratio was 6.09 (95% CI: 2.11 to 17.6). Figure 3A , revealing its linear increase over time during the 12-month follow-up. The incidence at 12 months was estimated to be 2%. During the follow-up period, 11 patients interrupted their anti- 1,2) . However, the population in these trials was limited; FP lesions treated The current study demonstrated that the predictive ability for restenosis, assessed by the area under the ROC curve, was statistically improved when IVUS data were used in addition to angiographic data.
ST INCIDENCE. Cumulative ST incidence is shown in
It is possible that IVUS provides more detailed and precise information on pre-and post-treatment vessel characteristics than angiography does. The current findings suggest that IVUS offers some help in predicting future risk of restenosis after DES implantation. However, the predictive ability did not seem to reach the level that was previously reported in coronary intervention (9, 10) . There remains room to improve the predictive ability for restenosis in FP intervention.
The 1-year ST incidence was 2%. It is of clinical note that the cumulative ST incidence rate did not reach the plateau but was linearly increased even after 3 months. Identification of its risk factors is needed. In addition, the current study, conducted in clinical settings, included a few patients interrupting antiplatelet therapy after DES implantation and observed that the interruption markedly increased the ST risk. The importance of continuing antiplatelet therapy was reconfirmed.
STUDY LIMITATIONS. First, the current study included only Japanese patients, and results should be confirmed in other ethnic groups. Second, this study was not designed to compare the durability of Zilver PTX implantation with other treatments. It remains to be studied whether Zilver PTX implantation is superior to other treatments in real-world settings.
Third, IVUS was not performed for all cases.
In addition, it was manually used for lesion assessment. However, we believe that little heterogeneity existed in usage and evaluation of IVUS, based on a common agreement in clinical practice of coronary intervention.
Fourth, the IVUS assessment in initial treatment and the DUS assessment for restenosis were not conducted under core laboratory review, simply because we could not raise enough research funds to conduct them. Although this might undermine the reliability of restenosis assessment, each participating site has clinical experience conducting pivotal trials on nitinol stents for FP lesions. We believe that these accumulated experiences minimized the variability. Fifth, the times to restenosis or ST were not exactly assessed because of variable time intervals between symptom onset and assessment. Sixth, the current study enrolled the lesions in which the DES was successfully deployed; therefore, we were unable to collect the data regarding the success rate.
CONCLUSIONS
We demonstrated real-world 1-year outcomes after Zilver PTX implantation for FP lesions, including challenging cases. Lesion length, EEM area, and MSA were independent predictors for restenosis.
